Abstract
Thirty nine patients with metastatic breast cancer, all previously treated with chemotherapy including anthracycline, were given Elliptinium acetate (80 mg/m2/day) and a continous infusion of Vinblastine (2 mg/m2day) for 3 consecutive days every 4 weeks. Twenty nine patients had measurable metastatic disease. Nine (31%) achieved a partial response. No complete response was observed. Median duration of response was 6 months. The response rate was dependent on the number of metastatic sites and independent of the number of previous chemotherapy regimes. Side effects were dry mouth (27 patients), vomiting (9), neutropenia (3 patients with grade IV, 2 with grade III), muscle cramps (5) and thrombosis (3). Xerostomia and vomiting contributed to weight loss and fatigue (8 patients). We conclude that Elliptinium-Vinblastine combination has moderate activity as second line treatment in metastatic breast cancer. This combination causes xerostomia and fatigue with moderate myelosuppression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Canellos GP: Treatment of metastases. In: Harris JRet al. (eds) Breast Diseases, JP Lippincott, Philadelphia, 1987, 385–479
Paoletti C, Le Pecq JB, Dat-Xuong N, Juret P, Gamier H, Amiel JL, Rouesse J: Antitumor activity, pharmacology and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy-ellipticinium (NSC 264137). Recent Results Cancer Res 74:107–123, 1980
Multon E, Riou JF, Lefèvre D, Ahomadegbe JC, Riou G: Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417. Biochemical Pharmacology 38:2077–2086, 1989
Juret P, Heron JF, Couette JE, Delozier T, Le Talaer JY: Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience. Cancer Treat Rep 66:1909–1916, 1982
Clarysse A, Brugarolas A, Siegenthaler P, Abele R, Cavalli F, de Jager R, Renard G, Rozencweig M, Hansen HH: Phase II study of 9-hydroxy-2N-methylellipticinium acetate. Eur J Cancer Clin Oncol 20:243–247, 1984
Rouësse JG, Le Chevalier T, Caille P, Mondesir JM, Sancho-Garnier H, May-Levin F, Spielmann M, De Jager R, Amiel JL: Phase II study of elliptinium in advanced breast cancer. Cancer Treat Rep 69:707–708, 1985
Treat J, Greenspan A, Rahman A, McCabe MS, Byrne PJ: Elliptinium: phase II study in advanced measurable breast cancer. Invest New Drugs 7:231–234, 1989
Buzdar A, Hortobagyi G, Esparza L, Holmes F, Ro J, Fraschini G, Lichtiger B: Elliptinium acetate in metastatic breast cancer — a phase II study. Oncology 47:101–104, 1990
Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G: Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer 56:225–229, 1985
Mondesir J-M, Bidart J-M, Goodman A, Alberici GF, Caille Ph, Troalen F, Rouesse J, Bohuon C, Gralla RJ, Einzig A-I, Buzdar A-U: Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysis. J Clin Oncol 3:735–740, 1985
Spielmann M, Rouessé J, Mondesir JM, Goodman A, Soupart A, Lechevalier T, Amiel JL: Elliptinium (E)-mitomycin (M)+VP16 (V) or vinblastine (VBL) in advanced breast cancer. Proc Am Soc Clin Oncol 5:241, 1986
World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO offset publication, Geneva, 1979, p 48
Einzig AI, Gralla RJ, Leyland-Jones BR: Phase I trial of elliptiunium (2-methyl-9-hydroxyellipticinium). Proc Am Soc Cancer Res 24:656, 1983
Buzdar A, Yap HY, Goodman A, Chou C, Hortobayi G, Blumenschein G, Benjamin R, Bodey G: Phase I trial of elliptinium acetate in advanced cancer. Proc Am Soc Cancer Res 25:722, 1984
Ingle JN, Ahmann DL, Gerstner JG, Green SJ, O'Connell MJ, Kvols LK: Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer. Cancer Treat Rep 68:803–804, 1984
Tannock I, Erlichman C, Perrault D, Quirt I, King M: Failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory breast cancer. Cancer Treat Rep 66:1783–1784, 1982
Shah NK, Creech RN, Catalo O, St Marie K: Phase II study of vinblastine infusion in the treatment of refractory breast cancer. Proc Am Soc Clin Oncol 1:73, 1982
Chacon RD, Kotliar ML, Cavarra G, Longarte EA, Marantz AB, Escobar N, Abraham M, Bloch J: Phase II study with vinblastine continuous infusion. Proc Am Soc Clin Oncol 1:33, 1982
Pierga JY, Spielmann M, Bertaud P, Le Chevalir T, Mezlini A, Guillot T, Theodore C, Tursz T: Chemotherapy solvage with elliptinium mitomycin-VP16 or vinblastine in advanced breast cancer. Breast Cancer Res Treat 14: Abstr 45:144, 1989
Chauvergne J, Durand M, Mauriac L, David M, Bui BN, Burucoa B, Ravaud A: Association d'etoposide et d'elliptinium dans le traitement palliatif des cancers avancés du sein. Traitement des Cancers du Sein, Sem. Hôp Paris 66:53–59, 1990
Mignot L, Belpomme D, Pujade-Lauraine E, Heritier F, Le Rol A, Marty M, Marie FN: A combination of 2-methyl-9-elliptinium and etoposide in resistant breast cancer bone metastasis: a phase II clinical trial. Proc Eur Soc Med Oncol 10:184, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kayitalire, L., Thomas, F., Le Chevalier, T. et al. Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer. Invest New Drugs 10, 303–307 (1992). https://doi.org/10.1007/BF00944185
Issue Date:
DOI: https://doi.org/10.1007/BF00944185